Wilson Disease

CAMBRIDGE, Mass., July 23, 2026 Prime Medicine (Nasdaq: PRME) announced that the U.S. Food and Drug Administration (FDA) has...

WILMETTE, Ill., June 26, 2026 Monopar Therapeutics announced new analyses from its Phase 3 FoCus clinical trial demonstrating that...

CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...

WILMETTE, Ill., May 19, 2026 Monopar Therapeutics announced the publication of new Phase 2 clinical trial data showing that...

Wilmette, Illinois, USA, April 19, 2026 In a significant advancement for rare disease therapeutics, Monopar Therapeutics Inc. has presented...

WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...